Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.

Applying for disability benefits is complicated. Blogger Trevis Gleason encourages people with multiple sclerosis to reach out to friends with MS for help with navigating the process.

A review of a disability benefit is not expected to make "crude proposals" on changes to claimants' payments, the minister ...

Nanocurcumin was linked to better disability scores in small RRMS trials, but researchers say larger studies are needed.

bDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark cDepartment of Neurology and Center of Clinical Neuroscience, First Faculty ...

Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) Copilot can monitor disease progression in patients w ...

A single-center observational cohort (n=116; 81% RRMS) receiving ocrelizumab from 2018–2023 enabled longitudinal tracking of IgG, IgA, and IgM across treatment cycles. Serial dosing produced gradual ...

Multiple sclerosis (MS) can have a substantial impact on many aspects of life beyond physical health, with 51% of people reporting that the disease affects their social life and 48% reporting that it ...

Sanofi’s Cenrifki (tolebrutinib) has been approved by the European Commission to treat secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. This follows the positive ...

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant ...

Cenrifki represents a significant advancement for people living with SPMS by targeting disability progression Approval based on the HERCULES phase 3 study in nrSPMS with supporting data from the ...

Late-onset multiple sclerosis (LOMS) is linked to faster disability progression. Disability in LOMS often progresses independently of relapses or MRI activity. Current treatments may not fully address ...